MedTech Dive February 25, 2025
Wall Street applauded the deal, sending shares of Solventum, the 3M spinoff, up 10% on Tuesday.
Dive Brief:
- Thermo Fisher Scientific agreed to pay about $4.1 billion in cash to acquire Solventum’s purification and filtration business.
- The technologies, used in the production of biologics and medical devices and for industrial applications, generated about $1 billion in revenue last year. The business employs about 2,500 people globally and will become part of Thermo Fisher’s life sciences solutions segment.
- The Solventum unit is highly complementary to Thermo Fisher’s bioproduction business that offers cell culture media and single-use technologies, Thermo Fisher CEO Marc Casper said in the Tuesday announcement.
Dive Insight:
Solventum’s filters and membranes are used to manufacture biopharmaceutical and...
Today's Sponsors
Today's Sponsor